SNS01-T: Interim Phase Ib/IIa data

Interim data from 3 evaluable patients in the second cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that 0.05 mg/kg SNS01-T led to 1 case of stable disease in a MM patient at...